Gov. Tony Evers, together with the Wisconsin Economic Development Corporation (WEDC), today announced that the state will support Eli Lilly and Company’s $4 billion investment in Wisconsin with up to $100 million in performance-based state tax credits.

“I’m proud of my administration’s efforts to invest in new economic opportunities, expansions, and developments in Southeastern Wisconsin in recent years with leading brands like Eli Lilly and Company moving and growing their operations here,” said Gov. Evers. “Coupled with our state’s designation as a U.S. Regional Tech Hub, history of game-changing innovations, and world-class manufacturing, Wisconsin is proud to partner with Lilly as they make this historic investment in our communities. This is great news for Wisconsin.”

Last year, Gov. Evers joined Lilly officials to announce that their expansion project in Bristol will extend the company’s global parenteral (injectable) product manufacturing network, helping to meet the growing demand for its diabetes, obesity, and future pipeline medicines across therapeutic areas. Lilly expects to add 750 highly skilled jobs to the current 100-plus workforce at this location.

“We are grateful for the partnership and leadership shown by Gov. Evers, WEDC, state, county, and local officials, as well as other stakeholders in supporting this project,” said Executive Vice President and President of Lilly Manufacturing Operations Edgardo Hernandez. “Together, we’re advancing innovative manufacturing capabilities, building capacity for the medicines of tomorrow, creating high-quality jobs, and ensuring that patients here and around the world have access to life-changing treatments. We look forward to contributing to the region’s strong legacy of innovation and economic vitality for years to come.”

The Evers Administration, through WEDC, began working on the expansion with the company and local leaders last year, following Lilly’s acquisition of a sterile injectables manufacturing plant in Pleasant Prairie owned by Nexus Pharmaceuticals. WEDC had also assisted Nexus Pharmaceuticals in moving its manufacturing operations from Illinois to Wisconsin in 2019. The acquisition, expansion, and additional purchases of land and adjacent warehouse bring Lilly’s total planned investment in Wisconsin to $4 billion.

Read more at WisPolitics.com.